BBIO FY 2025 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena

BBIOBridgeBio Pharma, Inc.

$14B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$502M+126.3% YoY

Gross Profit

$474M94.4% margin

Operating Income

-$569M-113.3% margin

Net Income

-$729M-145.3% margin

EPS (Diluted)

$-3.79

Cash Flow

Operating Cash Flow

-$446M

Free Cash Flow

-$447M

Stock-Based Comp.

$133M

Balance Sheet

Total Assets

$936M

Total Liabilities

$3.0B

Stockholders' Equity

-$2.1B

Cash & Equivalents

$570M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$502M	$222M	+126.3%
Gross Profit	$474M	$218M	+117.3%
Operating Income	-$569M	-$593M	+4.0%
Net Income	-$729M	-$536M	-36.1%